Metabrain Research, a Chilly Mazarin, France based innovative biotechnology company focused on the early development of drugs for the treatment of type 2 diabetes and inflammatory diseases announced today the signature of an agreement with Medicxi, a European life sciences venture capital firm, for the inception of Kymo Therapeutics Ltd, incorporated in Cambridge (UK).
Under the terms of the deal, Kymo will receive up to €10m from Medicxi.
Kymo Therapeutics’ formation aims to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and ensure commercialization.
Led by Dr. Valerie Autier, CEO, Metabrain is an innovative biotechnology company focused on the early development of drugs for the treatment of type 2 diabetes and inflammatory diseases. Benefiting from its R&D platform, it leverages its expertise on kynurenine metabolism to bringing therapeutic customized solutions to elderly and frail patients and allowing their treatment efficacy tracking.
FinSMEs
06/10/2016